Method of treating a subject suffering from end stage renal disease against cardiovascular disease
    21.
    发明授权
    Method of treating a subject suffering from end stage renal disease against cardiovascular disease 有权
    治疗终末期肾病患者抗心血管疾病的方法

    公开(公告)号:US08657775B2

    公开(公告)日:2014-02-25

    申请号:US12585054

    申请日:2009-09-01

    摘要: The present invention relates to high cut-off hemodialysis membranes for the treatment of chronic hemodialysis (CHD) patients, with the potential to improve long-term survival of these patients by reducing the risk of cardiovascular disease, through down-regulation of monocyte activation in the blood. Monocytes are the major circulating blood cells involved in the progression of cardiovascular disease. High cut-off hemodialysis in chronic dialysis patients results in a sustained decrease in expression of monocyte cell-surface proteins that direct the movement of these cells from the blood to the walls of blood vessels, where they promote the progression of arterial disease (atherosclerosis) that leads to cardiovascular disease (CVD); heart disease, strokes and peripheral vascular disease.

    摘要翻译: 本发明涉及用于治疗慢性血液透析(CHD)患者的高截止血液透析膜,可通过降低心血管疾病的风险来改善这些患者的长期存活,通过下调单核细胞活化 血液。 单核细胞是涉及心血管疾病进展的主要循环血细胞。 慢性透析患者的高截止血液透析导致单核细胞表面蛋白质的表达持续下降,从而将这些细胞从血液移动到血管壁,在那里它们促进动脉疾病(动脉粥样硬化)的进展, 导致心血管疾病(CVD); 心脏病,中风和外周血管疾病。

    Method of removing antibody free light chains from blood
    25.
    发明授权
    Method of removing antibody free light chains from blood 有权
    从血液中清除抗体自由轻链的方法

    公开(公告)号:US07875183B2

    公开(公告)日:2011-01-25

    申请号:US11599849

    申请日:2006-11-15

    摘要: There is provided a method of reducing blood free light chain concentration in a subject, the method comprising the step of subjecting the subject's blood to haemodialysis, haemodiafiltration or haemofiltration. There is also provided the use of a dialysis membrane which is a membrane that allows passage of molecules having a molecular weight of up to 45 kDa in presence of whole blood, and has a molecular weight exclusion limit in water of about 200 kDa in the preparation of a haemodialysis unit for conducting haemodialysis, haemodiafiltration or haemofiltration on a subject to reduce blood free light chain concentration in the patient.

    摘要翻译: 本发明提供减少受试者血液中无血液轻链浓度的方法,该方法包括使受试者的血液进行血液透析,血液透析或血液透析的步骤。 还提供了透析膜的使用,该透析膜是允许在全血存在下具有高达45kDa分子量的分子通过的膜,并且在制剂中具有约200kDa水分子排阻极限 的血液透析单元,用于对受试者进行血液透析,血液透析过滤或血液过滤,以减少患者中的血液轻链浓度。

    Membrane and use thereof
    26.
    发明授权
    Membrane and use thereof 失效
    膜及其用途

    公开(公告)号:US07644825B2

    公开(公告)日:2010-01-12

    申请号:US10532131

    申请日:2003-10-17

    摘要: The membrane producible by shaping a polymer blend or a block copolymer comprising blocks of monomer units, loading the polymer blend or block copolymer with a blowing gas concentration within the polymer blend or block polymer above a critical concentration at a temperature below a critical temperature, but above the glass transition temperature of the polymer blend/gas or block copolymer/gas mixture and finally stabilizing the foam structure is characterized in that as polymer blend a homogeneous polymer blend comprising at least one hydrophilic and at least one hydrophobic polymer and/or a block copolymer of alternating blocks of hydrophilic and hydrophobic monomer units is used, both the polymer blend and the block copolymer having a solubility relating to the used foaming gas above the critical concentration. The said membrane is used for medical purposes, especially for the haemodialysis, haemofiltration, haemodiafiltration, plasmapherese, immunotherapy, micro- or ultrafiltration or gas separation.

    摘要翻译: 该膜可以通过将包含单体单元的嵌段的聚合物共混物或嵌段共聚物成型,将聚合物共混物或嵌段共聚物以高于临界温度的临界浓度的聚合物共混物或嵌段聚合物内的吹入气体浓度加载, 高于聚合物共混物/气体或嵌段共聚物/气体混合物的玻璃化转变温度,并且最终稳定泡沫结构的特征在于,作为聚合物共混物,包含至少一种亲水和至少一种疏水性聚合物和/或嵌段的均匀聚合物共混物 使用亲水和疏水单体单元的交替嵌段的共聚物,聚合物共混物和嵌段共聚物具有高于临界浓度的所用发泡气体的溶解度。 所述膜用于医疗目的,特别用于血液透析,血液透析,血液透析,血浆置换,免疫治疗,微量或超滤或气体分离。

    Membrane and use thereof
    27.
    发明申请
    Membrane and use thereof 失效
    膜及其用途

    公开(公告)号:US20060138044A1

    公开(公告)日:2006-06-29

    申请号:US10532131

    申请日:2003-10-17

    IPC分类号: B01D71/68

    摘要: The membrane producible by shaping a polymer blend or a block copolymer comprising blocks of monomer units, loading the polymer blend or block copolymer with a blowing gas concentration within the polymer blend or block polymer above a critical concentration at a temperature below a critical temperature, but above the glass transition temperature of the polymer blend/gas or block copolymer/gas mixture and finally stabilizing the foam structure is characterized in that as polymer blend a homogeneous polymer blend comprising at least one hydrophilic and at least one hydrophobic polymer and/or a block copolymer of alternating blocks of hydrophilic and hydrophobic monomer units is used, both the polymer blend and the block copolymer having a solubility relating to the used foaming gas above the critical concentration. The said membrane is used for medical purposes, especially for the haemodialysis, haemofiltration, haemodiafiltration, plasmapherese, immunotherapy, micro- or ultrafiltration or gas separation.

    摘要翻译: 该膜可以通过将包含单体单元的嵌段的聚合物共混物或嵌段共聚物成型,将聚合物共混物或嵌段共聚物以高于临界温度的临界浓度的聚合物共混物或嵌段聚合物内的吹入气体浓度加载, 高于聚合物共混物/气体或嵌段共聚物/气体混合物的玻璃化转变温度,并且最终稳定泡沫结构的特征在于,作为聚合物共混物,包含至少一种亲水和至少一种疏水性聚合物和/或嵌段的均匀聚合物共混物 使用亲水和疏水单体单元的交替嵌段的共聚物,聚合物共混物和嵌段共聚物具有高于临界浓度的所用发泡气体的溶解度。 所述膜用于医疗目的,特别用于血液透析,血液透析,血液透析,血浆置换,免疫治疗,微量或超滤或气体分离。